Perbedaan Rerata Kadar Soluble Fms-Like Tyrosine Kinase-1 (Sflt-1) Serum pada Penderita Early Onset, Late Onset Preeklampsia Berat / Eklampsia dan Kehamilan Normal

<p><strong>Abstrak</strong></p><p>Preeklampsia merupakan sumber utama morbiditas dan mortalitas ibu di seluruh dunia. Kegagalan pengaturan dan ketidakseimbangan agen vasoaktif proangiogenik dan antiangiogenik plasenta, <em>soluble fms</em><em>-like tyr...

Full description

Bibliographic Details
Main Authors: Laila Rahmi, Rahmatina B. Herman, Yusrawati .
Format: Article
Language:English
Published: Universitas Andalas 2016-01-01
Series:Jurnal Kesehatan Andalas
Online Access:http://jurnal.fk.unand.ac.id/index.php/jka/article/view/440
id doaj-3ec76b53e4d14426b690329f5e9def03
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Laila Rahmi
Rahmatina B. Herman
Yusrawati .
spellingShingle Laila Rahmi
Rahmatina B. Herman
Yusrawati .
Perbedaan Rerata Kadar Soluble Fms-Like Tyrosine Kinase-1 (Sflt-1) Serum pada Penderita Early Onset, Late Onset Preeklampsia Berat / Eklampsia dan Kehamilan Normal
Jurnal Kesehatan Andalas
author_facet Laila Rahmi
Rahmatina B. Herman
Yusrawati .
author_sort Laila Rahmi
title Perbedaan Rerata Kadar Soluble Fms-Like Tyrosine Kinase-1 (Sflt-1) Serum pada Penderita Early Onset, Late Onset Preeklampsia Berat / Eklampsia dan Kehamilan Normal
title_short Perbedaan Rerata Kadar Soluble Fms-Like Tyrosine Kinase-1 (Sflt-1) Serum pada Penderita Early Onset, Late Onset Preeklampsia Berat / Eklampsia dan Kehamilan Normal
title_full Perbedaan Rerata Kadar Soluble Fms-Like Tyrosine Kinase-1 (Sflt-1) Serum pada Penderita Early Onset, Late Onset Preeklampsia Berat / Eklampsia dan Kehamilan Normal
title_fullStr Perbedaan Rerata Kadar Soluble Fms-Like Tyrosine Kinase-1 (Sflt-1) Serum pada Penderita Early Onset, Late Onset Preeklampsia Berat / Eklampsia dan Kehamilan Normal
title_full_unstemmed Perbedaan Rerata Kadar Soluble Fms-Like Tyrosine Kinase-1 (Sflt-1) Serum pada Penderita Early Onset, Late Onset Preeklampsia Berat / Eklampsia dan Kehamilan Normal
title_sort perbedaan rerata kadar soluble fms-like tyrosine kinase-1 (sflt-1) serum pada penderita early onset, late onset preeklampsia berat / eklampsia dan kehamilan normal
publisher Universitas Andalas
series Jurnal Kesehatan Andalas
issn 2301-7406
publishDate 2016-01-01
description <p><strong>Abstrak</strong></p><p>Preeklampsia merupakan sumber utama morbiditas dan mortalitas ibu di seluruh dunia. Kegagalan pengaturan dan ketidakseimbangan agen vasoaktif proangiogenik dan antiangiogenik plasenta, <em>soluble fms</em><em>-like tyrosine kinase</em>-1 (sFlt-1), <em>vascular endothelial growth factor</em> (VEGF) dan <em>placental growth factor</em> (PlGF) memainkan peran penting dalam patogenesis preeklampsia. Tujuan penelitian ini adalah menentukan perbedaan rerata kadar sFlt-1 serum pada penderita <em>early onset,</em> <em>late onset</em> preeklampsia berat/ eklampsia dan kehamilan normal.<strong> </strong>Penelitian dilakukan di RSUP Dr. M. Djamil, RS TK. III dr. Reksodiwiryo dan Laboratorium Biologi Molekuler Fakultas Kedokteran Universitas Andalas Padang dari Februari sampai  Desember 2014 dengan desain <em>cross sectional</em>. Subjek berjumlah 84 orang, terdiri dari tiga kelompok, yaitu kelompok <em>early onset</em> preeklampsia berat/ eklampsia<em>, late onset </em>preeklampsia berat/ eklampsia,<em> </em>dan<em> </em>kehamilan normal sebagai kelompok kontrol yang diambil dengan teknik <em>consecutive sampling</em>. Darah dikumpulkan dari subjek penelitian dengan cara intravena kemudian diukur dengan metode ELISA.<strong> </strong>Rerata kadar sFlt-1 pada kelompok <em>early onset, late onset </em>preeklampsia berat/ eklampsia<em> </em>dan<em> </em>kehamilan normal secara berturut-turut adalah 4,69±0,96 ng/ml, 2,39±0,57 ng/ml, dan 1,23±0,42 ng/ml. Perbedaan ini sangat signifikan dengan uji statistik ANOVA (<em>p</em>&lt;0,05) dan uji<em> Post Hoc Test<strong> </strong>Multiple<strong> </strong>Comparisons.</em> Kesimpulan penelitian adalah terdapat perbedaan yang sangat signifikan antara kadar sFlt-1 serum pada kelompok <em>early onset</em> preeklampsia berat/ eklampsia<em>, late onset </em>preeklampsia berat/ eklampsia<em> </em>dan<em> </em>kehamilan normal.<strong></strong></p><p><strong>Kata kunci:</strong> sFlt-1, antiangiogenik, preeklampsia berat/ eklampsia, kehamilan normal</p><p> </p><p><strong><em>Abstract</em></strong><strong><em></em></strong></p><p><em>Preeclampsia is a major cause maternal morbidity and mortality in the world. Failure regulation and imbalance of vasoactive agents and antiangiogenic proangiogenik placenta, soluble fms-like tyrosine kinase-1 (sFlt-1), vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) have an important role in the pathogenesis of preeclampsia. The objective of this study was to determine the differences between the mean serum levels of sFlt-1 in patients with early onset, late onset severe preeclampsia/eclampsia and normal pregnancy.</em><em> </em><em>This study was conducted in Dr. M. Djamil hospital, dr. Reksodiwiryo </em><em>TK. </em><em>III hospital and Biology Moleculer Laboratory Medicine Faculty of Andalas University Padang from February until December 2014 with a cross sectional design. The total subjects were 84 persons, consist of three groups, there was early onset severe preeclampsia/ eclampsia, late onset severe preeclampsia/ eclampsia and normal pregnancy as control group. The subjects were selected by consecutive sampling technique. The blood was collected by intravenous,  then sFlt-1 serum measured by ELISA.</em><em> </em><em>The mean levels of sFlt-1 in the early onset group, late onset severe preeclampsia/ eclampsia group and normal pregnancy group were 4</em><em>.</em><em>69±0</em><em>.</em><em>96 ng/ml, 2</em><em>.</em><em>39±0</em><em>.</em><em>57 ng/ml and 1</em><em>.</em><em>23±0</em><em>.</em><em>42 ng/ml. This difference very significant by ANOVA statisctical test (p&lt;0,05) and Multiple Comparisons Post Hoc Test.</em><em> </em><em>The conclusion of this study is </em><em>very significant differences between serum levels of sFlt-1 in early onset severe preeclampsia/ eclampsia group, late onset severe preeclampsia/ eclampsia on  normal pregnancy.</em><em></em></p><p><strong><em>Keywords:</em></strong><strong><em> </em></strong><em>sFlt-1, </em><em>antiangiogenic, </em><em>severe preeclampsia/</em><em> eclampsia,</em><em> </em><em>normal pregnancy</em><em></em></p>
url http://jurnal.fk.unand.ac.id/index.php/jka/article/view/440
work_keys_str_mv AT lailarahmi perbedaanreratakadarsolublefmsliketyrosinekinase1sflt1serumpadapenderitaearlyonsetlateonsetpreeklampsiaberateklampsiadankehamilannormal
AT rahmatinabherman perbedaanreratakadarsolublefmsliketyrosinekinase1sflt1serumpadapenderitaearlyonsetlateonsetpreeklampsiaberateklampsiadankehamilannormal
AT yusrawati perbedaanreratakadarsolublefmsliketyrosinekinase1sflt1serumpadapenderitaearlyonsetlateonsetpreeklampsiaberateklampsiadankehamilannormal
_version_ 1725122737677008896
spelling doaj-3ec76b53e4d14426b690329f5e9def032020-11-25T01:23:21ZengUniversitas AndalasJurnal Kesehatan Andalas 2301-74062016-01-0151374Perbedaan Rerata Kadar Soluble Fms-Like Tyrosine Kinase-1 (Sflt-1) Serum pada Penderita Early Onset, Late Onset Preeklampsia Berat / Eklampsia dan Kehamilan NormalLaila RahmiRahmatina B. HermanYusrawati .<p><strong>Abstrak</strong></p><p>Preeklampsia merupakan sumber utama morbiditas dan mortalitas ibu di seluruh dunia. Kegagalan pengaturan dan ketidakseimbangan agen vasoaktif proangiogenik dan antiangiogenik plasenta, <em>soluble fms</em><em>-like tyrosine kinase</em>-1 (sFlt-1), <em>vascular endothelial growth factor</em> (VEGF) dan <em>placental growth factor</em> (PlGF) memainkan peran penting dalam patogenesis preeklampsia. Tujuan penelitian ini adalah menentukan perbedaan rerata kadar sFlt-1 serum pada penderita <em>early onset,</em> <em>late onset</em> preeklampsia berat/ eklampsia dan kehamilan normal.<strong> </strong>Penelitian dilakukan di RSUP Dr. M. Djamil, RS TK. III dr. Reksodiwiryo dan Laboratorium Biologi Molekuler Fakultas Kedokteran Universitas Andalas Padang dari Februari sampai  Desember 2014 dengan desain <em>cross sectional</em>. Subjek berjumlah 84 orang, terdiri dari tiga kelompok, yaitu kelompok <em>early onset</em> preeklampsia berat/ eklampsia<em>, late onset </em>preeklampsia berat/ eklampsia,<em> </em>dan<em> </em>kehamilan normal sebagai kelompok kontrol yang diambil dengan teknik <em>consecutive sampling</em>. Darah dikumpulkan dari subjek penelitian dengan cara intravena kemudian diukur dengan metode ELISA.<strong> </strong>Rerata kadar sFlt-1 pada kelompok <em>early onset, late onset </em>preeklampsia berat/ eklampsia<em> </em>dan<em> </em>kehamilan normal secara berturut-turut adalah 4,69±0,96 ng/ml, 2,39±0,57 ng/ml, dan 1,23±0,42 ng/ml. Perbedaan ini sangat signifikan dengan uji statistik ANOVA (<em>p</em>&lt;0,05) dan uji<em> Post Hoc Test<strong> </strong>Multiple<strong> </strong>Comparisons.</em> Kesimpulan penelitian adalah terdapat perbedaan yang sangat signifikan antara kadar sFlt-1 serum pada kelompok <em>early onset</em> preeklampsia berat/ eklampsia<em>, late onset </em>preeklampsia berat/ eklampsia<em> </em>dan<em> </em>kehamilan normal.<strong></strong></p><p><strong>Kata kunci:</strong> sFlt-1, antiangiogenik, preeklampsia berat/ eklampsia, kehamilan normal</p><p> </p><p><strong><em>Abstract</em></strong><strong><em></em></strong></p><p><em>Preeclampsia is a major cause maternal morbidity and mortality in the world. Failure regulation and imbalance of vasoactive agents and antiangiogenic proangiogenik placenta, soluble fms-like tyrosine kinase-1 (sFlt-1), vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) have an important role in the pathogenesis of preeclampsia. The objective of this study was to determine the differences between the mean serum levels of sFlt-1 in patients with early onset, late onset severe preeclampsia/eclampsia and normal pregnancy.</em><em> </em><em>This study was conducted in Dr. M. Djamil hospital, dr. Reksodiwiryo </em><em>TK. </em><em>III hospital and Biology Moleculer Laboratory Medicine Faculty of Andalas University Padang from February until December 2014 with a cross sectional design. The total subjects were 84 persons, consist of three groups, there was early onset severe preeclampsia/ eclampsia, late onset severe preeclampsia/ eclampsia and normal pregnancy as control group. The subjects were selected by consecutive sampling technique. The blood was collected by intravenous,  then sFlt-1 serum measured by ELISA.</em><em> </em><em>The mean levels of sFlt-1 in the early onset group, late onset severe preeclampsia/ eclampsia group and normal pregnancy group were 4</em><em>.</em><em>69±0</em><em>.</em><em>96 ng/ml, 2</em><em>.</em><em>39±0</em><em>.</em><em>57 ng/ml and 1</em><em>.</em><em>23±0</em><em>.</em><em>42 ng/ml. This difference very significant by ANOVA statisctical test (p&lt;0,05) and Multiple Comparisons Post Hoc Test.</em><em> </em><em>The conclusion of this study is </em><em>very significant differences between serum levels of sFlt-1 in early onset severe preeclampsia/ eclampsia group, late onset severe preeclampsia/ eclampsia on  normal pregnancy.</em><em></em></p><p><strong><em>Keywords:</em></strong><strong><em> </em></strong><em>sFlt-1, </em><em>antiangiogenic, </em><em>severe preeclampsia/</em><em> eclampsia,</em><em> </em><em>normal pregnancy</em><em></em></p>http://jurnal.fk.unand.ac.id/index.php/jka/article/view/440